1. 346 Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/advanced solid tumors. (September 2015) Authors: Nayak, A.; Hao, Z.; Sadek, R.; Dobbins, R.; Marshall, L.; Vahanian, N.; Ramsey, J.; Kennedy, E.; Mautino, M.; Link, C.; Lin, R.; Royer-Joo, S.; Morrissey, K.; Mahrus, S.; McCall, B.; Pirzkall, A.; Munn, D.; Janik, J.; Khleif, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S69 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. (November 2017) Authors: El Osta, B.; Hu, F.; Sadek, R.; Chintalapally, R.; Tang, S.-C. Journal: Critical reviews in oncology/hematology Issue: Volume 119(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗